Evaluation of health-related quality of life in hemolytic uraemic syndrome patients treated with eculizumab: a systematic evaluation on basis of EMPRO

References

• Gasser C, Gautier E, Siebenmann R. Hämolytisch-urämische Syndrome im Kindesalter[Hemolytic uremic syndromes in childhood Fifth Congress of the European Society of Hematology]. In: Fünfter Kongress Der Europäischen Gesellschaft Für Hämatologie. Berlin, Heidelberg: Springer Science + Business Media; 1956. p. 787–788.
   Google Scholar
• Michael M, Elliott EJ, Craig JC, et al. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009;53:259–272.
   PubMed Web of Science ®Google Scholar
• Taylor CM, Machin S, Wigmore SJ, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol. 2010;148:37–47.
   PubMed Web of Science ®Google Scholar
• Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60.
   PubMed Web of Science ®Google Scholar
• Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676–1687.
   PubMed Web of Science ®Google Scholar
• Kandhare AD, Patil MV, Bodhankar SLL. Arginine attenuates the ethylene glycol induced urolithiasis in ininephrectomized hypertensive rats: role of KIM-1, NGAL, and NOs. Ren Fail. 2015;37:709–721.
   PubMed Web of Science ®Google Scholar
• Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554–562.
   PubMed Web of Science ®Google Scholar
• Visnagri A, Kandhare AD, Bodhankar SL. Renoprotective effect of berberine via intonation on apoptosis and mitochondrial-dependent pathway in renal ischemia reperfusion-induced mutilation. Ren Fail. 2015;37:482–493.
   PubMed Web of Science ®Google Scholar
• Kavanagh D, Richards A, Goodship T, et al. Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost. 2010;36:653–659.
   PubMed Web of Science ®Google Scholar
• Adil M, Kandhare AD, Ghosh P, et al. Ameliorative effect of naringin in acetaminophen-induced hepatic and renal toxicity in laboratory rats: role of FXR and KIM-1. Ren Fail. 2016;38:1007–1020.
   PubMed Web of Science ®Google Scholar
• Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643–657.
   PubMed Web of Science ®Google Scholar
• Saland JM, Ruggenenti P, Remuzzi G, et al. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2009;20:940–949.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Soliris® (eculizumab) [prescribing information]. Cheshire (CT): Alexion Pharmaceuticals, Inc.; 2014.
   Google Scholar
• European Medicines Agency. Soliris® (eculizumab) [prescribing information]. Paris, France: Alexion Europe; 2015.
   Google Scholar
• Ghosh P, Kandhare AD, Kumar VS, et al. Determination of clinical outcome and pharmacoeconomics of anti–rheumatoid arthritis therapy using CDAI, EQ–5D–3L and EQ–VAS as indices of disease amelioration. Asian Pac J Trop Dis. 2012;2:S671–S678.
   Google Scholar
• Shivakumar V, Kandhare AD, Rajmane AR, et al. Estimation of the long-term cardiovascular events using ukpds risk engine in metabolic syndrome patients. Indian J Pharm Sci. 2014;76:174–178.
   PubMed Web of Science ®Google Scholar
• Ghosh P, Kandhare AD, Raygude KS, et al. Determination of the long term diabetes related complications and cardiovascular events using UKPDS risk engine and UKPDS outcomes model in a representative western Indian population. Asian Pac J Trop Dis. 2012;2:S642–S650.
   Google Scholar
• Centers for Disease Control Prevention. Measuring healthy days: population assessment of health-related quality of life. Atlanta: CDC; 2000.
   Google Scholar
• Dole S, Kandhare AD, Ghosh P, et al. Homeopathic analgesic formulations: a critical appraisal of evidence. J Pharm Biomed Sci. 2012;22:1–6.
   Google Scholar
• Ghosh P, Kandhare AD, Raygude KS, et al. Cigarette smoking and H. pylori infection: a meta-analysis of literature. Pharm Lett. 2012;4:128–134.
   Google Scholar
• Ware JE, Kosinski M, Bjorner JB, et al. User’s manual for the SF-36v2 Health Survey. 2nd ed. Lincoln (RI): Quality Metric; 2008.
   Google Scholar
• Wenger NK, Mattson ME, Furberg CD, et al. Assessment of quality of life in clinical trials of cardiovascular therapies. Am J Cardiol. 1984;54:908–913.
   PubMed Web of Science ®Google Scholar
• Gosavi TP, Kumar VS, Kandhare AD, et al. A comprehensive metaanalysis and systematic review on effect of genistein on metabolic syndrome. Pharmacologia. 2015;5:120–126.
   Google Scholar
• Gosavi T, Ghosh P, Kandhare A, et al. Unwrapping homeopathic principles in the wake of research: serendipity, placebo or true therapeutic milestones. Pharmacologyonline. 2011;1:894–906.
   Google Scholar
• Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Fed Reg. 2009;74:65132–65133.
   Google Scholar
• Gosavi T, Kandhare A, Raygude K, et al. Evaluation of clinical outcome in arthritis with AIMS2. Deccan J Pharmacol. 2011;2:10–30.
   Google Scholar
• Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–2181.
   PubMed Web of Science ®Google Scholar
• Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89:701–711.
   PubMed Web of Science ®Google Scholar
• Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061–1073.
   PubMed Web of Science ®Google Scholar
• Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19:539–549.
   PubMed Web of Science ®Google Scholar
• Valderas JM, Ferrer M, Mendivil J, et al. Development of EMPRO: a tool for the standardized assessment of patient-reported outcome measures. Value Health. 2008;11:700–708.
   PubMed Web of Science ®Google Scholar
• Garin O, Herdman M, Vilagut G, et al. Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures. Heart Fail Rev. 2014;19:359–367.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Ferrer M, Gonzalez M, et al. Evaluation of shoulder-specific patient-reported outcome measures: a systematic and standardized comparison of available evidence. J Shoulder Elbow Surg. 2014;23:434–444.
   PubMed Web of Science ®Google Scholar
• Maratia S, Cedillo S, Rejas J. Assessing health-related quality of life in patients with breast cancer: a systematic and standardized comparison of available instruments using the EMPRO tool. Qual Life Res. 2016;25:2467–2480.
   PubMedGoogle Scholar
• Schmidt S, Garin O, Pardo Y, et al. Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments. Qual Life Res. 2014;23:2169–2181.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Kandhare AD, Mukherjee A, Ghosh P, et al. Efficacy of antioxidant in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Excli J. 2016;15:636–651.
   PubMed Web of Science ®Google Scholar
• Cochrane. Cochrane handbook for systematic reviews of interventions 5.0. 0. Indianapolis (IN): Cochrane Collaboration; 2008.
   Google Scholar
• van der Have M, van der Aalst KS, Kaptein AA, et al. Determinants of health-related quality of life in Crohn’s disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8:93–106.
   PubMed Web of Science ®Google Scholar
• Saultz JN, Wu HM, Cataland S. Headache prevalence following recovery from TTP and aHUS. Ann Hematol. 2015;94:1473–1476.
   PubMed Web of Science ®Google Scholar
• Muus P, Licht C, Goodship TH, et al. Eculizumab (ECU) significantly improves health-related quality of life (hrqol) in patients with atypical hemolytic uremic syndrome (aHUS). Blood. 2011;118:4772–4772.
   Google Scholar
• Licht C, Muus P, Legendre CM, et al. Eculizumab (ECU) safety and efficacy in atypical hemolytic uremic syndrome (aHUS) patients with long disease duration and chronic kidney disease (CKD): 2-year results. Blood. 2012;120:985–985.
   PubMed Web of Science ®Google Scholar
• Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab inhibits thrombotic microangiopathy and improves renal function in pediatric patients with atypical hemolytic uremic syndrome: 1-year update. Blood. 2014;124:4986–4986.
   Web of Science ®Google Scholar
• Greenbaum L, Legendre CM, Babu S, et al. Eculizumab (ECU) in atypical hemolytic uremic syndrome (aHUS) patients with progressing thrombotic microangiopathy (TMA): 2-year data. Blood. 2012;120:2084–2084.
   Web of Science ®Google Scholar
• Loirat C, Babu S, Furman R, et al. Eculizumab efficacy and safety in patients with atypical hemolytic uremic syndrome (aHus) resistant to plasma exchange/infusion. Poster session presented at: 16th Congress of European Hematology Association (EHA), London, United Kingdom; 2011.
   Google Scholar
• Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68:84–93.
   PubMed Web of Science ®Google Scholar
• Gunda P, Kandhare A, Nikoglou E, et al. A cost per responder analysis of secukinumab vs adalimumab based on a matching-adjusted indirect comparison for the treatment of ankylosing spondylitis from a German payer perspective. Value Health. 2016;19:A537.
   PubMed Web of Science ®Google Scholar
• Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med. 2016;7:39–72.
   PubMed Web of Science ®Google Scholar
• Riedl M, Hofer J, Giner T, et al. Monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome (aHUS) by measearing TCC capacity and C3a concentration. Paper presented at: Pediatric Nephrology, Shanghai, China; 2013.
   Google Scholar
• Rathbone J, Kaltenthaler E, Richards A, et al. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013;3:e003573.
   PubMed Web of Science ®Google Scholar
• Myers C, Wilks D. Comparison of EuroQol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Qual Life Res. 1999;8:9–16.
   PubMed Web of Science ®Google Scholar
• Brazier J, Jones N, Kind P. Testing the validity of the EuroQol and comparing it with the SF-36 health survey questionnaire. Qual Life Res. 1993;2:169–180.
   PubMed Web of Science ®Google Scholar
• Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528–538.
   PubMed Web of Science ®Google Scholar
• Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63–74.
   PubMed Web of Science ®Google Scholar
• Kosinski M, Gajria K, Fernandes AW, et al. Qualitative validation of the FACIT-fatigue scale in systemic lupus erythematosus. Lupus. 2013;22:422–430.
   PubMed Web of Science ®Google Scholar
• Lai JS, Beaumont JL, Ogale S, et al. Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. J Rheumatol. 2011;38:672–679.
   PubMed Web of Science ®Google Scholar
• Chandran V, Bhella S, Schentag C, et al. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66:936–939.
   PubMed Web of Science ®Google Scholar
• Signorovitch J, Brainsky A, Grotzinger KM. Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. Qual Life Res. 2011;20:1737–1744.
   PubMed Web of Science ®Google Scholar
• Hagell P, Hoglund A, Reimer J, et al. Measuring fatigue in Parkinson's disease: a psychometric study of two brief generic fatigue questionnaires. J Pain Symptom Manage. 2006;32:420–432.
   PubMed Web of Science ®Google Scholar
• Nachit‐Ouinekh F, Dartigues JF, et al. Use of the headache impact test (HIT‐6) in general practice: relationship with quality of life and severity. Eur J Neurol. 2005;12:189–193.
   PubMed Web of Science ®Google Scholar